a new vaccine produced by plants!

A research team succeeded in producing the glycoprotein top of the Coronavirus in investment and combine it with a excipient called AS03 to form their vaccine candidate. To test its efficacy and safety, an international randomized controlled phase III study was conducted placebo was conducted in 85 centers. Their results were published in the renowned journal The New England Journal of Medicine (NEJM) on May 4, 2022.

Half of the included patients received two placebo injections, the other half received two shots intramuscularly of the vaccine candidate at 21-day intervals. All included subjects (n=24,141) were adults; the average age was 29 years. The primary endpoint was the measurement of vaccine efficacy in prevention a symptomatic form of coronavirus disease that occurs within 7 days of the second injection. A coronavirus infection was confirmed by a test PCR.

A vaccine that works against 5 variants!

A total of 165 people tested positive SARS-CoV-2. A portion (73.9%) of the samples could be sequenced. that Variant Delta was responsible for 56 cases (45.9%), the gamma variant for 53 cases (43.4%), the alpha variant for 6 cases (4.9%), the mu variant for 4 cases (3, 3%) and the lambda variant for 3 cases (2.5%).

The effectiveness of the vaccine was:

  • 69.5% against symptomatic forms of the disease (all intensities combined);
  • 78.8% against moderate to severe symptomatic forms of the disease.

Furthermore, no severe cases occurred in the vaccinated group, while three severe cases were reported in the placebo group. That viral load was much lower in the vaccinated group. The side effects were mild or moderate and transient. Although they occurred more frequently in the vaccinated group than in the placebo group (92.3% vs. 45.5%) in the days following the injection, theA hit was similar in both groups 3 weeks after injection of each dose.

A study with limitations

The authors regret not being able to test the efficacy of their vaccine candidate against the Omicron variant, which is now dominant worldwide but was not yet in circulation at the time of the study. This topic will be the subject of a future publication.

This study has another limitation: very few patients over the age of 65 could be included in the study, despite this age group virus done for today most victims.

This herbal vaccine shows promise against delta and gamma variants of SARS-CoV-2

Article by Stephanie le Guillou published on February 15, 2022.

How to convince the most reluctant to get vaccinated? By offering vaccines using technologies other thanmessenger RNA. After the Novavax vaccine, the Canadian company Medicago unveils the promising results of its herbal vaccine.

As of February 14, 2022, nearly 53 million people in France were on a full vaccination schedule. The acceptance of vaccination card increased the numbers a bit. A glass ceiling seems to have been reached. So how do you convince the most reluctant to get vaccinated? There are several reasons to delay vaccination. among them, Rejection of vaccines based on messenger RNA technology comes first. The Novavax vaccine, soon to be available in France and based on more traditional technologies, could make it possible to increase vaccination coverage. Interestingly, the results of a plant-based vaccine candidate have just been published in Canada released.

The vaccine effectively prevents moderate to severe forms

This is a phase III, randomized, double-blind, placebo-controlled study conducted in Argentina, Brazil, Canada, Mexico, the United Kingdom and the United States. The vaccination schedule consisted of two intramuscular injections 21 days apart. The primary endpoint was the prevention of symptoms of a SARS-CoV-2 infection. The samples could be sequenced. Contaminated persons were mostly infected with the delta variant (n=45.9%) or the gamma variant (n=43.4%).

A total of 24,141 people were included in the study. Of these, 157 people were infected, 118 in the control group and 39 in the vaccinated group. The vaccine is therefore 71% effective in preventing symptomatic forms of Covid-19. Regarding the moderate to severe forms of the disease, 32 developed in the control group versus 8 in the vaccinated group. Efficacy against moderate to severe forms of the disease is 84.5% (excluding people who were positive at baseline). Side effects were very rare and not serious.

How it works ?

The plant used is a cousin of tobacco, which is considered a weed. It has an excellent yield of protein production. The principle is as follows. A non-toxic bacterial vector for the plant was injected plasmid contains the ashamed who codes for the protein spike of the virus. The plant is then brought into contact with these bacteria : The plant’s cellular machinery produces the spike protein and then expels it. All that remains is to get it back.

The application was submitted to Health Canada in late 2021 and could be approved in the coming weeks. In addition, this technology, which combines the traditional technique of virus particles and an innovative technique to produce them in a plant, can be transferred to other diseases.

Interested in what you just read?

Leave a Comment